NephroGenex
Princeton
About NephroGenex
NephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $21.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2015)
- Ticker: nasdaq:NRX
- Website: nephrogenex.com
- Phone: +1 609-986-1780
Industries & Categories
Biotechnology, Diabetes, Health Care
Social Profiles
Canonical: https://fsome.com/organization/nephrogenex-506560 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.